Lumicell, Inc

Lumicell, Inc. is a medical technology company founded in 2009 as a spinout from MIT that specializes in fluorescence-guided imaging systems for intraoperative tumor detection and resection. The company's core platform, LumiSystem, combines LUMISIGHT (a fluorescent optical contrast agent) with the Lumicell Direct Visualization System (DVS), a handheld real-time imaging device for surgical guidance. In April 2024, both LUMISIGHT and DVS received FDA approval as the first drug-device combination approved in over a decade for this indication. The technology is designed to help surgeons identify and remove residual cancer tissue while preserving healthy tissue during breast cancer lumpectomies and other oncologic procedures. Lumicell has validated its approach in clinical studies involving over 700 breast cancer patients and is expanding applications to solid tumors including gastric and gastrointestinal cancers.